Seelos Therapeutics, Inc. (SEEL)


+0.01 (+0.65%)
Symbol SEEL
Price $0.93
Beta 2.454
Volume Avg. 1.15M
Market Cap 99.223M
Shares () -
52 Week Range 0.48-2.79
1y Target Est -
DCF Unlevered SEEL DCF ->
DCF Levered SEEL LDCF ->
ROE -145.17% Strong Sell
ROA -139.27% Strong Sell
Operating Margin -
Debt / Equity 100.81% Buy
P/E -
P/B 3.76 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest SEEL news

Mr. Raj Mehra
NASDAQ Capital Market

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.